The role of prostanoid receptors in mediating the effects of PGE2 on human platelet function

Platelets

Volumn 21, Issue 5, 2010, Pages 329-342

  Iyú, David ^a   Glenn, Jackie R ^a   White, Ann E ^a   Johnson, Andrew J ^a   Fox, Susan C ^a   Heptinstall, Stan ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

Calcium signaling; EP receptors; P selectin; Platelet function; Prostaglandin E2; VASP phosphorylation

Indexed keywords

15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; CAY 10441; CAY10441; DG 041; ILOPROST; ONO 8713; ONO AE1 259; ONO AE1 329; ONO AE3 208; ONO AEI 259; ONO DI 004; PADGEM PROTEIN; PROSTAGLANDIN E RECEPTOR; PROSTAGLANDIN E2; PROSTAGLANDIN RECEPTOR BLOCKING AGENT; PROSTAGLANDIN RECEPTOR STIMULATING AGENT; PROSTANOID RECEPTOR; SULPROSTONE; THROMBIN RECEPTOR ACTIVATING PEPTIDE 6; THROMBOCYTE ACTIVATING FACTOR; THROMBOXANE A2; UNCLASSIFIED DRUG; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR; VASODILATOR STIMULATED PHOSPHOPROTEIN; 4-(4-CYANO-2-(2-(4-FLUORONAPHTHALEN-1-YL)PROPIONYLAMINO)PHENYL)BUTYRIC ACID; ACTIN BINDING PROTEIN; ARYLBUTYRIC ACID DERIVATIVE; CELL ADHESION MOLECULE; CYCLIC AMP; NAPHTHALENE DERIVATIVE; OLIGOPEPTIDE; PHOSPHOPROTEIN; PROSTAGLANDIN E RECEPTOR 3; PROSTAGLANDIN E RECEPTOR 4; PTGER3 PROTEIN, HUMAN; PTGER4 PROTEIN, HUMAN; SER-PHE-PHE-LEU-ARG-ASN; VASODILATOR-STIMULATED PHOSPHOPROTEIN;

ARTICLE; CALCIUM SIGNALING; CONTROLLED STUDY; DRUG RESPONSE; DRUG SELECTIVITY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; THROMBOCYTE; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; THROMBOCYTE RICH PLASMA; VENOUS BLOOD; AGONISTS; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; BLOOD; DRUG EFFECTS; METABOLISM; PHOSPHORYLATION; PHYSIOLOGY;

15-HYDROXY-11 ALPHA,9 ALPHA-(EPOXYMETHANO)PROSTA-5,13-DIENOIC ACID; BLOOD PLATELETS; CALCIUM SIGNALING; CELL ADHESION MOLECULES; CYCLIC AMP; DINOPROSTONE; HUMANS; MICROFILAMENT PROTEINS; NAPHTHALENES; OLIGOPEPTIDES; P-SELECTIN; PHENYLBUTYRATES; PHOSPHOPROTEINS; PHOSPHORYLATION; PLATELET ACTIVATING FACTOR; PLATELET AGGREGATION; RECEPTORS, PROSTAGLANDIN E; RECEPTORS, PROSTAGLANDIN E, EP3 SUBTYPE; RECEPTORS, PROSTAGLANDIN E, EP4 SUBTYPE;

EID: 77954791521     PISSN: 09537104     EISSN: 13691635     Source Type: Journal    
DOI: 10.3109/09537101003718065     Document Type: Article

References (35)

1. Shio H, Ramwell P, Jessup SJ. Prostaglandin E2: Effects on aggregation, shape change and cAMP of rat platelets. Prostaglandins 1971;1:29-36.
2. Salzman EW, Kensler PC, Levine L. Cyclic 30,50-adenosine monophosphate in human blood platelets. IV. Regulatory role of cyclic AMP in platelet function. Ann N Y Acad Sci 1972;201:61-71.
3. Weiss HJ, Willis AL, Kuhn D, Brand H. Prostaglandin E2 potentiation of platelet aggregation induced by LASS endoperoxide: Absent in storage pool disease, normal after aspirin ingestion. Br J Haematol 1976;32:257-272.
4. Tynan SS, Anderson NH, Wills MT, Harker AA, Hanson SR. On the multiplicity of platelet prostaglandin receptors II. The use of N-0164 for distinguishing the loci of action for PGI2, PGD2, PGE2 and hydantoin analogues. Prostaglandins 1984;27:683-696.
5. Gray SJ, Heptinstall S. The effects of PGE2 and CL 115,347, an antihypertensive PGE2 analogue, on human blood platelet behaviour and vascular contractility. Eur J Pharmacol 1985;114:129-137.
6. Gray SJ, Heptinstall S. Interactions between prostaglandin E2 and inhibitors of platelet aggregation which act through cyclic AMP. Eur J Pharmacol 1991;194:63-70.
7. Matthews JS, Jones RL. Potentiation of aggregation and inhibition of adenylyl cyclase in human platelets by prostaglandin E analogues. Br J Pharmacol 1993;108:363-369.
8. Vezza R, Roberti R, Nenci GG, Gresele P. Prostaglandin E2 potentiates aggregation by priming protein kinase C. Blood 1993;82:2704-2713.
9. Gresele P, Blockmans D, Deckmyn H, Vermylen J. Adenylaste cyclise activation determines the effect of thromboxane synthase inhibitors on platelet aggregation in vitro. Comparisons of platelets from responders and non-responders. J Pharmacol Exp Ther 1998;246:301-307.
10. Fabre JE, Nguyen M, Athirakul K, Coggins K, McNeish JD, Austin S, Parise LK, FitzGerald GA, Coffman TM, Koller BH. Activation of the murine EP3 receptor for PGE2 inhibits cAMP production and promotes platelet aggregation. J Clin Invest 2001;107:603-610.
11. Ma H, Hara A, Xiao CY, Okada Y, Takahata O, Nakaya K, Sugimoto Y, Ichikawa A, Narumiya S, Ushikubi F. Increased bleeding tendency and decreased susceptibility to thromboembolism in mice lacking the prostaglandin E receptor subtype EP(3). Circulation 2001;104:1176-1180.
12. Gross S, Tilly P, Hentsch D, Vonesch JL, Fabre JE. Vascular wall-produced prostaglandin E2 exacerbates arterial thrombosis and atherothrombosis through platelet EP3 receptors. J Exp Med 2007;204:311-320.
13. Heptinstall S, Espinosa DI, Manolopoulos P, Glenn JR, White AE, Johnson A, Dovlatova N, Fox SC, May JA, Hermann D, et al. DG-041 inhibits the EP3 prostanoid receptor - a new target for inhibition of platelet function in atherothrombotic disease. Platelets 2008;19:605-613.
14. Singh J, Zeller W, Zhou N, Hategan G, Mishra R, Polozov, Yu P, Onua E, Zhang J, Zembower D, et al. Identification of DG-041, a potent and selective, prostanoid EP3 receptor antagonist, as a novel anti-platelet agent. ACS Chem Biol 2009;4:115-126.
15. Maayani S, Schwarz TE, Patel ND, Craddock-Royal BD, Tagliente TM. Diversity of signalling underlying responses mediated by selective activation of the platelet thromboxane A2 (TXA2) receptor; pharmacological and kinetic studies in vitro. Platelets 2003;14:359-374.
16. Dovlatova N, Wijeyeratne YD, Fox SC, Manolopoulos P, Johnson AJ, White AE, Latif ML, Ralevic V, Heptinstall S. Detection of P2Y14 protein in platelets and investigation of the role of P2Y14 in platelet function in comparison with the EP3 receptor. Thromb Haemost 2008;100:261-270.
17. Coleman RA, Smith WL, Narumiya S. International Union of Pharmacology classification of prostanoid receptors: Properties, distribution, and structure of the receptors and their subtypes. Pharmacol Rev 1994;46:205-229.
18. Narumiya S, Sugimoto Y, Ushikubi F. Prostanoid receptors: structures, properties, and functions. Physiol Rev 1999;79:193-226.
19. Sugimoto Y, Narumiya S. Prostaglandin E receptors. J Biol Chem 2007;282:11613-11617.
20. Paul BZ, Ashby B, Sheth SB. Distribution of prostaglandin IP and EP receptor subtypes and isoforms in platelets and human umbilical artery smooth muscle cells. Br J Haematol 1998;102:1204-1211.
21. Maruyama T, Ochuchida S. Selective agonists and antagonists for prostaglandin E2 receptor subtypes. Tanpakushitsu Kakusan Koso 2000;45(6 Suppl):1001-1007.
22. Norel X. Prostanoid receptors in the human vascular wall. Scientific World Journal. 2007;7:1359-1374.
23. Dey I, Giembycz MA, Chadee K. Prostaglandin E2 couples through EP4 prostanoid receptors to induce IL-8 production in human colonic epithelial cell lines. Br J Pharmacol 2009;156:475-485.
24. Foudi N, Kotelevets L, Louedec L, Leseche G, Henin D, Chastre E, Norel X. Vasorelaxation induced by prostaglandin E2 in human pulmonary vein: Role of the EP4 receptor subtype. Br J Pharmacol 2008;154:1631-1639.
25. Jones RL, Wise H, Clark R, Whiting RL, Bley KR. Investigation of the prostacyclin (IP) receptor antagonist RO1138452 on isolated blood vessel and platelet preparations. Br J Pharmacol 2006;149:110-120.
26. Butt E, Abel K, Krieger M, Palm D, Hoppe V, Hoppe J, Walter U. cAMP- and cGMP-dependent protein kinase phosphorylation sites of the focal adhesion vasodilatorstimulated phosphoprotein (VASP) in vitro and in intact human platelets. J Biol Chem 1994;269:14509-14517.
27. Comerford KM, Lawrence DW, Synnestvedt K, Levi BP, Colgan SP. Role of vasodilator-stimulated phosphoprotein in PKA-induced changes in endothelial junctional permeability. FASEB J 2002;16:583-585.
28. Watanabe K, Kawamori T, Nakatsugi S, Ohta T, Ohuchida S, Yamamoto H, Maruyama T, Kondo K, Ushikubi F, Narumiya S, et al. Role of the prostaglandin E receptor subtype EP1 in colon carcinogenesis. Cancer Res 1999;59:5093-5096.
29. Watanabe K, Kawamori T, Nakatsugi S, Ohta T, Ohuchida S, Yamamoto H, Maruyama T, Kondo K, Narumiya S, Sugimura T, et al. Inhibitory effect of a prostaglandin E receptor subtype EP(1) selective antagonist, ONO-8713, on development of azoxymethane-induced aberrant crypt foci in mice. Cancer Lett 2000;156:57-61.
30. Matsuoka Y, Furuyashiki T, Bito H, Ushikubi F, Tanaka Y, Kobayashi T, Muro S, Satoh N, Kayahara T, Higashi M, et al. Impaired adrenocorticotropic hormone response to bacterial endotoxin in mice deficient in prostaglandin E receptor EP1 and EP3 subtypes. Proc Natl Acad Sci USA 2003;100:4132-4137.
31. Matsuoka Y, Furuyashiki T, Yamada K, Nagai T, Bito H, Tanaka Y, Kitaoka S, Ushikubi F, Nabeshima T, Narumiya S. Prostaglandin E receptor EP1 controls impulsive behavior under stress. Proc Natl Acad Sci USA 2005;102: 16066-16071.
32. Bradbury DA, Newton R, Zhu YM, El-Haroun H, Corbett L, Knox AJ. Cyclooxygenase-2 induction by bradykinin in human pulmonary artery smooth muscle cells is mediated by the cyclic AMP response element through a novel autocrine loop involving endogenous prostaglandin E2, Eprostanoid 2 (EP2), and EP4 receptors. J Biol Chem 2003;278:49954-49964.
33. Bradbury D, Clarke D, Seedhouse C, Corbett L, Stocks JA, Knox AJ. Vascular endothelial growth factor induction by prostaglandin E2 in human airway smooth muscle cells is mediated by E prostanoid EP2/EP4 receptors and SP-1 transcription factor binding sites. J Biol Chem 2005;280:29993-30000.
34. Suzawa T, Miyaura C, Inada M, Maruyama T, Sugimoto Y, Ushikubi F, Ichikawa A, Narumiya S, Suda T. The role of prostaglandin E receptor subtypes (EP1, EP2, EP3, and EP4) in bone resorption: An analysis using specific agonists for the respective EPs. Endocrinology 2000;141:1554-1559.
35. Mao G-F, Jin J-G, Bastepe M, Ortiz-Vega S, Ashby B. Prostaglandin E2 both stimulates and inhibits adenylyl cyclase on platelets: comparison of effects on cloned EP4 and EP3 prostaglandin receptor subtypes. Prostaglandins 1996;52: 175-185.